GC101 Adeno-Associated Virus Injection, the first intrathecally administered AAV gene therapy drug independently developed by Genecradle Therapeutics, has officially received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration to conduct a Phase III pivotal clinical trial for Type 2 5q spinal muscular atrophy (SMA).

Every April 15th is "International Pompe Disease Day." Established in 2014, this day aims to raise awareness of Pompe disease among all sectors of society and promote the development and application of research related to the disease.

The 28th Annual Meeting of the American Society of Gene&Cell Therapy(ASGCT)will be held in New Orleans,USA,from May 13 to 17,2025.Beijing Genecradle Therapeutics Technology Co.,Ltd.(hereinafter re

Genecradle Therapeutics was invited to participate in two major annual forums - the "2025 Boao Forum for Asia Annual Conference" and the "2025 Zhongguancun Forum Annual Conference." As a leading enterprise in the field of gene therapy in China, Genecradle made its voice heard in global health governance and technological innovation.

On February 28,2025,Genecradle Therapeutics'independently developed gene therapy drug for Pompe disease,GC301 Adeno-Associated Virus Injection,received Orphan Drug Designation(ODD)from the U.S.Food and Drug Administration(FDA).

On February 19, 2025, Beijing Genecradle Therapeutics Technology Co., Ltd. and Beijing Byongen Therapeutics Co., Ltd.formally signed a strategic cooperation agreement to jointly develop the next-generation gene therapy for Duchenne Muscular Dystrophy

On February 6, 2025, Genecradle Therapeutics' independently developed gene therapy drug, GC310 Adeno-Associated Virus Injection ("GC310 Injection"), received the tacit approval for registration of cli

On December 25th, the 8th Zhongguancun International Frontier Technology Competition in the biomedical field concluded successfully at the Dongsheng International Science Park in Zhongguancun. After i